Triple

T6003729
Position Surface form Disambiguated ID Type / Status
Subject Loxo Oncology E133655 entity
Predicate leadProduct P68639 FINISHED
Object larotrectinib E561035 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: larotrectinib | Statement: [Loxo Oncology, leadProduct, larotrectinib]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: larotrectinib
Context triple: [Loxo Oncology, leadProduct, larotrectinib]
  • A. larotrectinib chosen
    Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
  • B. selpercatinib
    Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
  • C. Imfinzi
    Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
  • D. Lynparza
    Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
  • E. Vitrakvi
    Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07 
Target predicate: leadProduct
Context triple: [Loxo Oncology, leadProduct, larotrectinib]
  • A. leadsInto
    Indicates that one entity serves as an entry or transition point that directly connects or opens into another entity.
  • B. leadsOrder
    Indicates that one entity holds primary responsibility or authority over the order associated with another entity.
  • C. leadSingle
    Indicates that an entity serves as the primary or featured performer, contributor, or focus in a single work or instance.
  • D. leads
    Indicates having primary responsibility for directing, guiding, or managing another entity or group toward a goal or outcome.
  • E. helpsLead
    Indicates that one entity assists or contributes to another entity’s act of leading or guiding.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c00872444c8190bfaf1739dcec765c completed March 22, 2026, 3:19 p.m.
NER Named-entity recognition batch_69c04f0f63148190826198281dce3713 completed March 22, 2026, 8:20 p.m.
NED1 Entity disambiguation (via context triple) batch_69c11365741c819097a43a49dd2428c1 completed March 23, 2026, 10:18 a.m.
PD Predicate disambiguation batch_69c049e3316c819087ea635fa7ee8472 completed March 22, 2026, 7:58 p.m.
PDg Predicate description generation batch_69c04e8c5bfc8190b986a7071d1b23e3 completed March 22, 2026, 8:18 p.m.
Created at: March 22, 2026, 4:06 p.m.